[1] SUNG H,FERLAY J,SIEGEL R L,et al.Global cancer statistics 2020:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J].CA Cancer J Clin,2021,71(3):209-249.
[2] HOWLADER N,ALTEKRUSE S F,LI C I,et al.US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status[J].J Natl Cancer Inst,2014,106(5):dju055.
[3] WAKS A G,WINER E P.Breast cancer treatment:a review[J].JAMA,2019,321(3):288-300.
[4] CIPRIANI A,HIGGINS J P T,GEDDES J R,et al.Conceptual and technical challenges in network Meta-analysis[J].Ann Intern Med,2013,159(2):130-137.
[5] IOANNIDIS J P A.Perfect study,poor evidence:interpretation of biases preceding study design[J].Semin Hematol,2008,45(3):160-166.
[6] WARNER J,YANG P,ALTEROVITZ G.Automated synthesis and visualization of a chemotherapy treatment regimen network[J].Stud Health Technol Inform,2013,192:62-66.
[7] WARNER J L,YANG P C,ALTEROVITZ G.Overcoming the straw man effect in oncology:visualization and ranking of chemotherapy regimens using an information theoretic approach[J].JCO Clin Cancer Inform,2017,1:1-9.
[8] HIGGINS J P T,ALTMAN D G,GØTZSCHE P C,et al.The Cochrane Collaboration's tool for assessing risk of bias in randomised trials[J].BMJ,2011,343:d5928.
[9] BENNETT J M,MUSS H B,DOROSHOW J H,et al.A randomized multicenter trial comparing mitoxantrone,cyclophosphamide,and fluorouracil with doxorubicin,cyclophosphamide,and fluorouracil in the therapy of metastatic breast carcinoma[J].J Clin Oncol,1988,6(10):1611-1620.
[10] MUSS H B,WELLS H B,PASCHOLD E H,et al.Megestrol acetate versus tamoxifen in advanced breast cancer:5-year analysis—a phase Ⅲ trial of the Piedmont Oncology Association[J].J Clin Oncol,1988,6(7):1098-1106.
[11] COCCONI G,BISAGNI G,CECI G,et al.Low-dose aminoglutethimide with and without hydrocortisone replacement as a first-line endocrine treatment in advanced breast cancer:a prospective randomized trial of the Italian Oncology Group for Clinical Research[J].J Clin Oncol,1992,10(6):984-989.
[12] GERSHANOVICH M,GARIN A,BALTINA D,et al.A phase Ⅲ comparison of two toremifene doses to tamoxifen in postmenopausal women with advanced breast cancer.Eastern European Study Group[J].Breast Cancer Res Treat,1997,45(3):251-262.
[13] BONNETERRE J,THVRLIMANN B,ROBERTSON J F,et al.Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women:results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study[J].J Clin Oncol,2000,18(22):3748-3757.
[14] SLEDGE G W Jr,HU P,FALKSON G,et al.Comparison of chemotherapy with chemohormonal therapy as first-line therapy for metastatic,hormone-sensitive breast cancer:an Eastern Cooperative Oncology Group study[J].J Clin Oncol,2000,18(2):262-266.
[15] MILLA-SANTOS A,MILLA L,RALLO L,et al.Phase Ⅲ randomized trial of toremifene vs tamoxifen in hormonodependant advanced breast cancer[J].Breast Cancer Res Treat,2001,65(2):119-124.
[16] MOURIDSEN H,GERSHANOVICH M,SUN Y,et al.Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer:results of a phase Ⅲ study of the International Letrozole Breast Cancer Group[J].J Clin Oncol,2001,19(10):2596-2606.
[17] BAJETTA E,PROCOPIO G,FERRARI L,et al.A randomized,multicenter prospective trial assessing long-acting release octreotide pamoate plus tamoxifen as a first line therapy for advanced breast carcinoma[J].Cancer,2002,94(2):299-304.
[18] BUZDAR A,HAYES D,EL-KHOUDARY A,et al.Phase Ⅲ randomized trial of droloxifene and tamoxifen as first-line endocrine treatment of ER/PgR-positive advanced breast cancer[J].Breast Cancer Res Treat,2002,73(2):161-175.
[19] BASELGA J,LLOMBART-CUSSAC A,BELLET M,et al.Randomized,double-blind,multicenter trial comparing two doses of arzoxifene(LY353381) in hormone-sensitive advanced or metastatic breast cancer patients[J].Ann Oncol,2003,14(9):1383-1390.
[20] BUZDAR A,O'SHAUGHNESSY J A,BOOSER D J,et al.Phase Ⅱ,randomized,double-blind study of two dose levels of arzoxifene in patients with locally advanced or metastatic breast cancer[J].J Clin Oncol,2003,21(6):1007-1014.
[21] MILLA-SANTOS A,MILLA L,PORTELLA J,et al.Anastrozole versus tamoxifen as first-line therapy in postmenopausal patients with hormone-dependent advanced breast cancer:a prospective,randomized,phase Ⅲ study[J].Am J Clin Oncol,2003,26(3):317-322.
[22] MOURIDSEN H,GERSHANOVICH M,SUN Y,et al.Phase Ⅲ study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women:analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group[J].J Clin Oncol,2003,21(11):2101-2109.
[23] HOWELL A,ROBERTSON J F R,ABRAM P,et al.Comparison of fulvestrant versus tamoxifen for the treatment of advanced breast cancer in postmenopausal women previously untreated with endocrine therapy:a multinational,double-blind,randomized trial[J].J Clin Oncol,2004,22(9):1605-1613.
[24] BOTTINI A,GENERALI D,BRIZZI M P,et al.Randomized phase Ⅱ trial of letrozole and letrozole plus low-dose metronomic oral cyclophosphamide as primary systemic treatment in elderly breast cancer patients[J].J Clin Oncol,2006,24(22):3623-3628.
[25] DESHMANE V,KRISHNAMURTHY S,MELEMED A S,et al.Phase Ⅲ double-blind trial of arzoxifene compared with tamoxifen for locally advanced or metastatic breast cancer[J].J Clin Oncol,2007,25(31):4967-4973.
[26] GOSS P,BONDARENKO I N,MANIKHAS G N,et al.Phase Ⅲ,double-blind,controlled trial of atamestane plus toremifene compared with letrozole in postmenopausal women with advanced receptor-positive breast cancer[J].J Clin Oncol,2007,25(31):4961-4966.
[27] JOHNSTON S,PIPPEN J Jr,PIVOT X,et al.Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer[J].J Clin Oncol,2009,27(33):5538-5546.
[28] ROBERTSON J F R,LLOMBART-CUSSAC A,ROLSKI J,et al.Activity of fulvestrant 500 mg versus anastrozole 1 mg as first-line treatment for advanced breast cancer:results from the FIRST study[J].J Clin Oncol,2009,27(27):4530-4535.
[29] BLOHMER J U,SCHMID P,HILFRICH J,et al.Epirubicin and cyclophosphamide versus epirubicin and docetaxel as first-line therapy for women with metastatic breast cancer:final results of a randomised phase Ⅲ trial[J].Ann Oncol,2010,21(7):1430-1435.
[30] CRISTOFANILLI M,VALERO V,MANGALIK A,et al.Phase Ⅱ,randomized trial to compare anastrozole combined with gefitinib or placebo in postmenopausal women with hormone receptor-positive metastatic breast cancer[J].Clin Cancer Res,2010,16(6):1904-1914.
[31] JOENSUU H,SAILAS L,ALANKO T,et al.Docetaxel versus docetaxel alternating with gemcitabine as treatments of advanced breast cancer:final analysis of a randomised trial[J].Ann Oncol,2010,21(5):968-973.
[32] MILES D W,CHAN A,DIRIX L Y,et al.Phase Ⅲ study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer[J].J Clin Oncol,2010,28(20):3239-3247.
[33] MARTIN M,ROCHE H,PINTER T,et al.Motesanib,or open-label bevacizumab,in combination with paclitaxel,as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer:a phase 2,randomised,double-blind,placebo-controlled study[J].Lancet Oncol,2011,12(4):369-376.
[34] NIELSEN D L,BJERRE K D,JAKOBSEN E H,et al.Gemcitabine plus docetaxel versus docetaxel in patients with predominantly human epidermal growth factor receptor 2-negative locally advanced or metastatic breast cancer:a randomized,phase Ⅲ study by the Danish Breast Cancer Cooperative Group[J].J Clin Oncol,2011,29(36):4748-4754.
[35] OSBORNE C K,NEVEN P,DIRIX L Y,et al.Gefitinib or placebo in combination with tamoxifen in patients with hormone receptor-positive metastatic breast cancer:a randomized phase Ⅱ study[J].Clin Cancer Res,2011,17(5):1147-1159.
[36] ROBERT N J,SALEH M N,PAUL D,et al.Sunitinib plus paclitaxel versus bevacizumab plus paclitaxel for first-line treatment of patients with advanced breast cancer:a phase Ⅲ,randomized,open-label trial[J].Clin Breast Cancer,2011,11(2):82-92.
[37] RYAN P D,NEVEN P,BLACKWELL K L,et al.P1-17-01:figitumumab plus exemestane versus exemestane as first-line treatment of postmenopausal hormone receptor-positive advanced breast cancer:a randomized,open-label phase Ⅱ trial[J].Cancer Res,2011,71(24_Supplement):P1-17-01-P1-17-01.
[38] STOCKLER M R,HARVEY V J,FRANCIS P A,et al.Capecitabine versus classical cyclophosphamide,methotrexate,and fluorouracil as first-line chemotherapy for advanced breast cancer[J].J Clin Oncol,2011,29(34):4498-4504.
[39] YARDLEY D A,BURRIS H A 3rd,CLARK B L,et al.Hormonal therapy plus bevacizumab in postmenopausal patients who have hormone receptor-positive metastatic breast cancer:a phase Ⅱ Trial of the Sarah Cannon Oncology Research Consortium[J].Clin Breast Cancer,2011,11(3):146-152.
[40] BASELGA J,SEGALLA J G M,ROCHÉ H,et al.Sorafenib in combination with capecitabine:an oral regimen for patients with HER2-negative locally advanced or metastatic breast cancer[J].J Clin Oncol,2012,30(13):1484-1491.
[41] BERGH J,JÖNSSON P E,LIDBRINK E K,et al.FACT:an open-label randomized phase Ⅲ study of fulvestrant and anastrozole in combination compared with anastrozole alone as first-line therapy for patients with receptor-positive postmenopausal breast cancer[J].J Clin Oncol,2012,30(16):1919-1925.
[42] CARLSON R W,O'NEILL A,VIDAURRE T,et al.A randomized trial of combination anastrozole plus gefitinib and of combination fulvestrant plus gefitinib in the treatment of postmenopausal women with hormone receptor positive metastatic breast cancer[J].Breast Cancer Res Treat,2012,133(3):1049-1056.
[43] HATSCHEK T,CARLSSON L,EINBEIGI Z,et al.Individually tailored treatment with epirubicin and paclitaxel with or without capecitabine as first-line chemotherapy in metastatic breast cancer:a randomized multicenter trial[J].Breast Cancer Res Treat,2012,131(3):939-947.
[44] ANTONIO LLOMBART-CUSSAC MD P,AMPARO RUIZ MD P,ANTONIO ANTÓN MD P,et al.Exemestane versus anastrozole as front-line endocrine therapy in postmenopausal patients with hormone receptor-positive,advanced breast cancer[J].Cancer,2012,118(1):241-247.
[45] MEHTA R S,BARLOW W E,ALBAIN K S,et al.Combination anastrozole and fulvestrant in metastatic breast cancer[J].N Engl J Med,2012,367(5):435-444.
[46] ROBERTSON J F R,LINDEMANN J P O,LLOMBART-CUSSAC A,et al.Fulvestrant 500 mg versus anastrozole 1 mg for the first-line treatment of advanced breast cancer:follow-up analysis from the randomized 'FIRST' study[J].Breast Cancer Res Treat,2012,136(2):503-511.
[47] GRADISHAR W J,KAKLAMANI V,SAHOO T P,et al.A double-blind,randomised,placebo-controlled,phase 2b study evaluating sorafenib in combination with paclitaxel as a first-line therapy in patients with HER2-negative advanced breast cancer[J].Eur J Cancer,2013,49(2):312-322.
[48] IWATA H,MASUDA N,OHNO S,et al.A randomized,double-blind,controlled study of exemestane versus anastrozole for the first-line treatment of postmenopausal Japanese women with hormone-receptor-positive advanced breast cancer[J].Breast Cancer Res Treat,2013,139(2):441-451.
[49] KAHÁN Z,PETRUZELKA L,ENIU A,et al.Abstract LB-177:first-line bevacizumab(BEV)+chemotherapy for hormone receptor-positive metastatic breast cancer(mBC):subgroup analysis of the open-label non-inferiority TURANDOT phase Ⅲ trial[J].Cancer Res,2013,73(8_Supplement):LB-177-LB-177.
[50] LANG I,BRODOWICZ T,RYVO L,et al.Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer:interim efficacy results of the randomised,open-label,non-inferiority,phase 3 TURANDOT trial[J].Lancet Oncol,2013,14(2):125-133.
[51] LVCK H J,BOIS A D,LOIBL S,et al.Capecitabine plus paclitaxel versus epirubicin plus paclitaxel as first-line treatment for metastatic breast cancer:efficacy and safety results of a randomized,phase Ⅲ trial by the AGO Breast Cancer Study Group[J].Breast Cancer Res Treat,2013,139(3):779-787.
[52] WOLFF A C,LAZAR A A,BONDARENKO I,et al.Randomized phase Ⅲ placebo-controlled trial of letrozole plus oral temsirolimus as first-line endocrine therapy in postmenopausal women with locally advanced or metastatic breast cancer[J].J Clin Oncol,2013,31(2):195-202.
[53] LAM S W,DE GROOT S M,HONKOOP A H,et al.Paclitaxel and bevacizumab with or without capecitabine as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer:a multicentre,open-label,randomised phase 2 trial[J].Eur J Cancer,2014,50(18):3077-3088.
[54] CLEMENS M R,GLADKOV O A,GARTNER E,et al.Phase Ⅱ,multicenter,open-label,randomized study of YM155 plus docetaxel as first-line treatment in patients with HER2-negative metastatic breast cancer[J].Breast Cancer Res Treat,2015,149(1):171-179.
[55] ELLIS M J,LLOMBART-CUSSAC A,FELTL D,et al.Fulvestrant 500 mg versus anastrozole 1 mg for the first-line treatment of advanced breast cancer:overall survival analysis from the phase Ⅱ FIRST study[J].J Clin Oncol,2015,33(32):3781-3787.
[56] FINN R S,CROWN J P,LANG I,et al.The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive,HER2-negative,advanced breast cancer(PALOMA-1/TRIO-18):a randomised phase 2 study[J].Lancet Oncol,2015,16(1):25-35.
[57] LVCK H J,LVBBE K,REINISCH M,et al.Phase Ⅲ study on efficacy of taxanes plus bevacizumab with or without capecitabine as first-line chemotherapy in metastatic breast cancer[J].Breast Cancer Res Treat,2015,149(1):141-149.
[58] MACKEY J R,RAMOS-VAZQUEZ M,LIPATOV O,et al.Primary results of ROSE/TRIO-12,a randomized placebo-controlled phase Ⅲ trial evaluating the addition of ramucirumab to first-line docetaxel chemotherapy in metastatic breast cancer[J].J Clin Oncol,2015,33(2):141-148.
[59] MARTÍN M,LOIBL S,VON MINCKWITZ G,et al.Phase Ⅲ trial evaluating the addition of bevacizumab to endocrine therapy as first-line treatment for advanced breast cancer:the letrozole/fulvestrant and avastin(LEA) study[J].J Clin Oncol,2015,33(9):1045-1052.
[60] DICKLER M N,BARRY W T,CIRRINCIONE C T,et al.Phase Ⅲ trial evaluating letrozole as first-line endocrine therapy with or without bevacizumab for the treatment of postmenopausal women with hormone receptor-positive advanced-stage breast cancer:CALGB 40503(alliance)[J].J Clin Oncol,2016,34(22):2602-2609.
[61] HORTOBAGYI G N,STEMMER S M,BURRIS H A,et al.Ribociclib as first-line therapy for HR-positive,advanced breast cancer[J].N Engl J Med,2016,375(18):1738-1748.
[62] IM S A,MUKAI H,PARK I H,et al.116O Palbociclib(PAL) plus letrozole(L) as first-line(1L) therapy(tx) in postmenopausal Asian women with estrogen receptor-positive(ER+)/human epidermal growth factor receptor 2-negative(HER2-) metastatic breast cancer(mBC)[J].Ann Oncol,2016,27:ix35.
[63] ROBERTSON J F R,BONDARENKO I M,TRISHKINA E,et al.Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer(FALCON):an international,randomised,double-blind,phase 3 trial[J].Lancet,2016,388(10063):2997-3005.
[64] WELT A,MARSCHNER N,LERCHENMUELLER C,et al.Capecitabine and bevacizumab with or without vinorelbine in first-line treatment of HER2/neu-negative metastatic or locally advanced breast cancer:final efficacy and safety data of the randomised,open-label superiority phase 3 CARIN trial[J].Breast Cancer Res Treat,2016,156(1):97-107.
[65] ZIELINSKI C,LÁNG I,INBAR M,et al.Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer(TURANDOT):primary endpoint results of a randomised,open-label,non-inferiority,phase 3 trial[J].Lancet Oncol,2016,17(9):1230-1239.
[66] GOETZ M P,TOI M,CAMPONE M,et al.MONARCH 3:abemaciclib as initial therapy for advanced breast cancer[J].J Clin Oncol,2017,35(32):3638-3646.
[67] YAMAMOTO D,SATO N,RAI Y,et al.Efficacy and safety of low-dose capecitabine plus docetaxel versus single-agent docetaxel in patients with anthracycline-pretreated HER2-negative metastatic breast cancer:results from the randomized phase Ⅲ JO21095 trial[J].Breast Cancer Res Treat,2017,161(3):473-482.
[68] HORTOBAGYI G N,STEMMER S M,BURRIS H A,et al.Updated results from MONALEESA-2,a phase Ⅲ trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive,HER2-negative advanced breast cancer[J].Ann Oncol,2018,29(7):1541-1547.
[69] MEHTA R S,BARLOW W E,ALBAIN K S,et al.Abstract PD5-07:a phase Ⅲ randomized trial of anastrozole and fulvestrant versus anastrozole or sequential anastrozole and fulvestrant as first-line therapy for postmenopausal women with metastatic breast cancer:final survival outcomes of SWOG S0226[J].Cancer Res,2018,78(4_Supplement):PD5-7-PD5-07.
[70] SLAMON D J,NEVEN P,CHIA S,et al.Phase Ⅲ randomized study of ribociclib and fulvestrant in hormone receptor-positive,human epidermal growth factor receptor 2-negative advanced breast cancer:MONALEESA-3[J].J Clin Oncol,2018,36(24):2465-2472.
[71] TRIPATHY D,IM S A,COLLEONI M,et al.Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive,advanced breast cancer(MONALEESA-7):a randomised phase 3 trial[J].Lancet Oncol,2018,19(7):904-915.
[72] IM S A,LU Y S,BARDIA A,et al.Overall survival with ribociclib plus endocrine therapy in breast cancer[J].N Engl J Med,2019,381(4):307-316.
[73] JOHNSTON S,MARTIN M,DI LEO A,et al.MONARCH 3 final PFS:a randomized study of abemaciclib as initial therapy for advanced breast cancer[J].NPJ Breast Cancer,2019,5:5.
[74] MAVRATZAS A,BAEK S,GERBER B,et al.Sorafenib in combination with docetaxel as first-line therapy for HER2-negative metastatic breast cancer:final results of the randomized,double-blind,placebo-controlled phase Ⅱ MADONNA study[J].Breast,2019,45:22-28.
[75] MEHTA R S,BARLOW W E,ALBAIN K S,et al.Overall survival with fulvestrant plus anastrozole in metastatic breast cancer[J].N Engl J Med,2019,380(13):1226-1234.
[76] PAUL D,VUKELJA S J,ANN HOLMES F,et al.Randomized phase-Ⅱ evaluation of letrozole plus dasatinib in hormone receptor positive metastatic breast cancer patients[J].NPJ Breast Cancer,2019,5:36.
[77] RUGO H S,FINN R S,DIÉRAS V,et al.Palbociclib plus letrozole as first-line therapy in estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer with extended follow-up[J].Breast Cancer Res Treat,2019,174(3):719-729.
[78] FINN R S,BOER K,BONDARENKO I,et al.Overall survival results from the randomized phase 2 study of palbociclib in combination with letrozole versus letrozole alone for first-line treatment of ER+/HER2-advanced breast cancer(PALOMA-1,TRIO-18)[J].Breast Cancer Res Treat,2020,183(2):419-428.
[79] KROP I,ABRAMSON V,COLLEONI M,et al.A randomized placebo controlled phase Ⅱ trial evaluating exemestane with or without enzalutamide in patients with hormone receptor-positive breast cancer[J].Clin Cancer Res,2020,26(23):6149-6157.
[80] SLAMON D J,NEVEN P,CHIA S,et al.Overall survival with ribociclib plus fulvestrant in advanced breast cancer[J].N Engl J Med,2020,382(6):514-524.
[81] ZHANG Q Y,SUN T,YIN Y M,et al.MONARCH plus:abemaciclib plus endocrine therapy in women with HR+/HER2-advanced breast cancer:the multinational randomized phase Ⅲ study[J].Ther Adv Med Oncol,2020,12:1758835920963925.
[82] LLOMBART-CUSSAC A,PÉREZ-GARCÍA J M,BELLET M,et al.Fulvestrant-palbociclib vs letrozole-palbociclib as initial therapy for endocrine-sensitive,hormone receptor-positive,ERBB2-negative advanced breast cancer:a randomized clinical trial[J].JAMA Oncol,2021,7(12):1791-1799.
[83] SLAMON D J,NEVEN P,CHIA S,et al.Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive,human epidermal growth factor receptor 2-negative advanced breast cancer in the phase Ⅲ randomized MONALEESA-3 trial:updated overall survival[J].Ann Oncol,2021,32(8):1015-1024.
[84] XU B,HU X,LI W,et al.228MO PALOMA-4:Primary results from a phase Ⅲ trial of palbociclib(PAL) + letrozole(LET) vs placebo(PBO)+LET in Asian postmenopausal women with estrogen receptor-positive/human epidermal growth factor receptor 2-negative(ER+/HER2-) advanced breast cancer(ABC)[J].Ann Oncol,2021,32:S457.
[85] ALBANELL J,MARTÍNEZ M T,RAMOS M,et al.Randomized phase Ⅱ study of fulvestrant plus palbociclib or placebo in endocrine-sensitive,hormone receptor-positive/HER2-advanced breast cancer:GEICAM/2014-12(FLIPPER)[J].Eur J Cancer,2022,161:26-37.
[86] BAHL A,WILSON W,BALL J,et al.Concept:a randomised multicentre trial of first line chemotherapy comparing three weekly cabazitaxel versus weekly paclitaxel in HER2 negative metastatic breast cancer[J].Breast,2022,66:69-76.
[87] FINN R S,RUGO H S,DIERAS V C,et al.Overall survival(OS) with first-line palbociclib plus letrozole(PAL+LET) versus placebo plus letrozole(PBO+LET) in women with estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer(ER+/HER2-ABC):analyses from PALOMA-2[J].J Clin Oncol,2022,40(17_suppl):LBA1003.
[88] HORTOBAGYI G N,STEMMER S M,BURRIS H A,et al.Overall survival with ribociclib plus letrozole in advanced breast cancer[J].N Engl J Med,2022,386(10):942-950.
[89] LU Y S,IM S A,COLLEONI M,et al.Updated overall survival of ribociclib plus endocrine therapy versus endocrine therapy alone in pre-and perimenopausal patients with HR+/HER2-advanced breast cancer in MONALEESA-7:a phase Ⅲ randomized clinical trial[J].Clin Cancer Res,2022,28(5):851-859.
[90] XU B,HU X,LI W,et al.Palbociclib plus letrozole versus placebo plus letrozole in Asian postmenopausal women with oestrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer:primary results from PALOMA-4[J].Eur J Cancer,2022,175:236-245.
[91] ABUDUREHEIYIMU N,WU Y,LI Q,et al.Docetaxel plus S-1 versus docetaxel plus capecitabine as first-line treatment for advanced breast cancer patients:a prospective randomized phase Ⅱ study[J].J Natl Cancer Cent,2023,3(2):115-120.
[92] NEVEN P,FASCHING P A,CHIA S,et al.Updated overall survival from the MONALEESA-3 trial in postmenopausal women with HR+/HER2-advanced breast cancer receiving first-line ribociclib plus fulvestrant[J].Breast Cancer Res,2023,25(1):103.
[93] WANG J,CAI L,SONG Y,et al.Clinical efficacy of fulvestrant versus exemestane as first-line therapies for Chinese postmenopausal oestrogen-receptor positive/human epidermal growth factor receptor 2-advanced breast cancer(FRIEND study)[J].Eur J Cancer,2023,184:73-82.
[94] ZHANG P,ZHANG Q,TONG Z,et al.Dalpiciclib plus letrozole or anastrozole versus placebo plus letrozole or anastrozole as first-line treatment in patients with hormone receptor-positive,HER2-negative advanced breast cancer(DAWNA-2):a multicentre,randomised,double-blind,placebo-controlled,phase 3 trial[J].Lancet Oncol,2023,24(6):646-657.
[95] CORTÉS J,HURVITZ S A,O'SHAUGHNESSY J,et al.Randomized phase Ⅲ study of amcenestrant plus palbociclib versus letrozole plus palbociclib in estrogen receptor-positive,human epidermal growth factor receptor 2-negative advanced breast cancer:primary results from AMEERA-5[J].J Clin Oncol,2024,42(22):2680-2690.
[96] GOETZ M P,TOI M,HUOBER J,et al.Abemaciclib plus a nonsteroidal aromatase inhibitor as initial therapy for HR+,HER2-advanced breast cancer:final overall survival results of MONARCH 3[J].Ann Oncol,2024,35(8):718-727.
[97] LU Y S,BIN MOHD MAHIDIN E I,AZIM H,et al.Final results of RIGHT choice:ribociclib plus endocrine therapy versus combination chemotherapy in premenopausal women with clinically aggressive hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer[J].J Clin Oncol,2024,42(23):2812-2821.
[98] NOGUCHI E,YAMANAKA T,MUKAI H,et al.A phase 3 study(PATHWAY) of palbociclib plus tamoxifen in patients with HR-positive/HER2-negative advanced breast cancer[J].NPJ Breast Cancer,2024,10(1):76.
[99] ORLANDO L,MAIELLO E,ORDITURA M,et al.Phase Ⅱ randomized trial comparing metronomic anthracycline-containing chemotherapy versus standard schedule in untreated HER2 negative advanced breast cancer:activity and quality of life results of the GOIM 21003 trial[J].Breast,2024,75:103725.
[100] SLAMON D J,DIÉRAS V,RUGO H S,et al.Overall survival with palbociclib plus letrozole in advanced breast cancer[J].J Clin Oncol,2024,42(9):994-1000.
[101] TAKAHASHI M,KIKAWA Y,KASHIWABARA K,et al.Eribulin versus S-1 as first or second-line chemotherapy to assess health-related quality of life and overall survival in HER2-negative metastatic breast cancer(RESQ study):a non-inferiority,randomised,controlled,open-label,phase 3 trial[J].EClinicalMedicine,2024,74:102715.
[102] ZIYEH S,WONG L,BASHO R K.Advances in endocrine therapy for hormone receptor-positive advanced breast cancer[J].Curr Oncol Rep,2023,25(7):689-698.
[103] 中国临床肿瘤学会指南工作委员会组织.中国临床肿瘤学会(CSCO)乳腺癌诊疗指南-2024[M].北京:人民卫生出版社,2024. |
